Table 4 Most common (> 5%) serious and non-serious treatment-emergent adverse events (TEAEs)
|  | Placebo (n = 47) | Meropenem (n = 44) | p value |
|---|---|---|---|
At least one serious TEAE, n (%) | 24 (51.1) | 27 (61.4) | 0.399 |
Type of serious TEAEs, n (%) | |||
 Severe anemia and blood transfusion | 4 (8.7) | 4 (9.1) | 1.00 |
 Hemoptysis | 0 | 3 (6.8) | 0.113 |
 New hospitalization | 7 (15.2) | 9 (20.5) | 0.588 |
At least one non-serious TEAE, n (%) | 44 (93.6) | 37 (84.1) | 0.188 |
Type of non-serious TEAEs, n (%) | |||
 Diarrhea | 7 (14.9) | 5 (11.4) | 0.605 |
 Constipation | 2 (4.3) | 4 (9.1) | 0.425 |
 Mild anemia | 4 (8.7) | 6 (13.6) | 0.518 |
 Thrombocytopenia | 5 (10.9) | 5 (11.4) | 1.00 |
 Eosinophilia | 3 (6.5) | 1 (2.3) | 0.617 |
 Increased creatinine | 4 (8.7) | 6 (13.6) | 0.518 |
 Increased liver enzymes | 9 (19.6) | 11 (25.6) | 0.613 |
 Blood coagulation disorders | 3 (6.5) | 3 (6.8) | 1.00 |
 Dyspnea | 3 (6.5) | 2 (4.5) | 1.00 |
 Rash | 6 (13) | 1 (2.3) | 0.111 |
 Peripheral edema | 3 (6.5) | 1 (2.3) | 0.617 |
 Hyperglycemia | 4 (8.7) | 1 (2.3) | 0.361 |
 Hypoglycemia | 2 (4.3) | 5 (11.4) | 0.257 |
 Hyponatremia | 5 (10.9) | 6 (13.6) | 0.755 |
 Hypokalemia | 11 (23.9) | 9 (20.5) | 0.802 |
 Hypophosphatemia | 3 (6.5) | 4 (9.1) | 0.711 |
 Hypomagnesemia | 2 (4.3) | 3 (6.8) | 0.673 |